As of 2025-07-11, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (34.12) USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.33 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -126.4%.
The range of the Relative Valuation is (33.18) - (34.92) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 14.5x | 14.3x |
| Forward P/E multiples | 13.2x - 14.8x | 14.0x |
| Fair Price | (33.18) - (34.92) | (34.12) |
| Upside | -125.7% - -127.0% | -126.4% |
| Date | P/E |
| 2025-07-08 | -53.25 |
| 2025-07-07 | -53.25 |
| 2025-07-03 | -53.23 |
| 2025-07-02 | -53.16 |
| 2025-07-01 | -53.22 |
| 2025-06-30 | -53.16 |
| 2025-06-27 | -53.13 |
| 2025-06-26 | -53.14 |
| 2025-06-25 | -53.18 |
| 2025-06-24 | -53.19 |
| 2025-06-23 | -53.25 |
| 2025-06-20 | -53.16 |
| 2025-06-18 | -53.13 |
| 2025-06-17 | -53.18 |
| 2025-06-16 | -53.18 |
| 2025-06-13 | -53.06 |
| 2025-06-12 | -53.17 |
| 2025-06-11 | -53.06 |
| 2025-06-10 | -53.07 |
| 2025-06-09 | -53.07 |
| 2025-06-06 | -53.02 |
| 2025-06-05 | -53.04 |
| 2025-06-04 | -53.12 |
| 2025-06-03 | -52.91 |
| 2025-06-02 | -52.99 |
| 2025-05-30 | -42.03 |
| 2025-05-29 | -42.74 |
| 2025-05-28 | -39.52 |
| 2025-05-27 | -41.49 |
| 2025-05-23 | -42.09 |
| 2025-05-22 | -41.61 |
| 2025-05-21 | -42.10 |
| 2025-05-20 | -42.71 |
| 2025-05-19 | -41.97 |
| 2025-05-16 | -42.17 |
| 2025-05-15 | -41.26 |
| 2025-05-14 | -40.44 |
| 2025-05-13 | -41.22 |
| 2025-05-12 | -41.60 |
| 2025-05-09 | -40.30 |
| 2025-05-08 | -40.95 |
| 2025-05-07 | -41.39 |
| 2025-05-06 | -41.12 |
| 2025-05-05 | -42.23 |
| 2025-05-02 | -43.39 |
| 2025-05-01 | -41.16 |
| 2025-04-30 | -37.11 |
| 2025-04-29 | -36.69 |
| 2025-04-28 | -36.70 |
| 2025-04-25 | -36.35 |